Masson GR, Williams RL. Structural Mechanisms of PTEN Regulation. Cold Spring Harb Perspect Med. 2020;10(3). https://doi.org/10.1101/cshperspect.a036152.
Fusco N, Malapelle U, Fassan M, Marchiò C, Buglioni S, Zupo S, et al. PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Front Oncol. 2021;11(562). https://doi.org/10.3389/fonc.2021.644737.
Carbognin L, Miglietta F, Paris I, Dieci MV. Prognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing Perspectives. Cancers (Basel). 2019;11(9). https://doi.org/10.3390/cancers11091401.
Lopez G, Noale M, Corti C, Gaudioso G, Sajjadi E, Venetis K, et al. PTEN Expression as a Complementary Biomarker for Mismatch Repair Testing in Breast Cancer. Int J Mol Sci. 2020;21(4). https://doi.org/10.3390/ijms21041461.
Vidwans SJ, Turski ML, Janku F, Garrido-Laguna I, Munoz J, Schwab R, et al. A framework for genomic biomarker actionability and its use in clinical decision making. Oncoscience. 2014;1(10):614–23. https://doi.org/10.18632/oncoscience.90.
Article
PubMed
PubMed Central
Google Scholar
Bazzichetto C, Conciatori F, Pallocca M, Falcone I, Fanciulli M, Cognetti F, et al. PTEN as a Prognostic/Predictive Biomarker in Cancer: An Unfulfilled Promise? Cancers (Basel). 2019;11(4):435.
Article
CAS
Google Scholar
Kingston B, Bailleux C, Delaloge S, Schiavon G, Scott V, Lacroix-Triki M, et al. Exceptional response to AKT inhibition in patients with breast Cancer and germline PTEN mutations. JCO Precision Oncol. 2019;(3):1–7. https://doi.org/10.1200/PO.19.00130.
Fabi A, Metro G, Di Benedetto A, Nisticò C, Vici P, Melucci E, et al. Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies. Oncology. 2010;78(2):141–9. https://doi.org/10.1159/000312656.
Article
CAS
PubMed
Google Scholar
Sajjadi E, Venetis K, Piciotti R, Invernizzi M, Guerini-Rocco E, Haricharan S, et al. Mismatch repair-deficient hormone receptor-positive breast cancers: biology and pathological characterization. Cancer Cell Int. 2021;21(1):266. https://doi.org/10.1186/s12935-021-01976-y.
Article
CAS
PubMed
PubMed Central
Google Scholar
Stern HM, Gardner H, Burzykowski T, Elatre W, O'Brien C, Lackner MR, et al. PTEN loss is associated with worse outcome in HER2-amplified breast Cancer patients but is not associated with Trastuzumab resistance. Clin Cancer Res. 2015;21(9):2065–74. https://doi.org/10.1158/1078-0432.CCR-14-2993.
Article
CAS
PubMed
PubMed Central
Google Scholar
Li S, Shen Y, Wang M, Yang J, Lv M, Li P, et al. Loss of PTEN expression in breast cancer: association with clinicopathological characteristics and prognosis. Oncotarget. 2017;8(19):32043–54. https://doi.org/10.18632/oncotarget.16761.
Article
PubMed
PubMed Central
Google Scholar
Perez EA, Dueck AC, McCullough AE, Chen B, Geiger XJ, Jenkins RB, et al. Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the north central Cancer treatment group N9831 trial. J Clin Oncol. 2013;31(17):2115–22. https://doi.org/10.1200/JCO.2012.42.2642.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nuciforo PG, Aura C, Holmes E, Prudkin L, Jimenez J, Martinez P, et al. Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status. Ann Oncol. 2015;26(7):1494–500. https://doi.org/10.1093/annonc/mdv175.
Article
CAS
PubMed
PubMed Central
Google Scholar
Fusco N, Sajjadi E, Venetis K, Gaudioso G, Lopez G, Corti C, et al. PTEN alterations and their role in Cancer management: are we making headway on precision medicine? Genes. 2020;11(7):719. https://doi.org/10.3390/genes11070719.
Article
CAS
PubMed Central
Google Scholar
Fusco N, Lopez G, Corti C, Pesenti C, Colapietro P, Ercoli G, et al. Mismatch Repair Protein Loss as a Prognostic and Predictive Biomarker in Breast Cancers Regardless of Microsatellite Instability. JNCI Cancer Spectr. 2018;2(4):pky056.
Article
Google Scholar
Tan PH, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S, et al. The 2019 World Health Organization classification of tumours of the breast. Histopathology. 2020;77(2):181–5. https://doi.org/10.1111/his.14091.
Article
PubMed
Google Scholar
Rakha EA, El-Sayed ME, Lee AH, Elston CW, Grainge MJ, Hodi Z, et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol. 2008;26(19):3153–8. https://doi.org/10.1200/JCO.2007.15.5986.
Article
PubMed
Google Scholar
Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, et al. AJCC Cancer staging manual. 8th edn: Springer International Publishing; 2017. https://doi.org/10.1007/978-3-319-40618-3.
Book
Google Scholar
Ercoli G, Lopez G, Ciapponi C, Corti C, Despini L, Gambini D, et al. Building up a high-throughput screening platform to assess the heterogeneity of HER2 gene amplification in breast cancers. J Vis Exp. 2017;13(1):233–6. https://doi.org/10.3791/56686.
Article
CAS
Google Scholar
Sciarra A, Lopez G, Corti C, Runza L, Ercoli G, Bonometti A, et al. Columnar cell lesion and apocrine hyperplasia of the breast: is there a common origin? The Role of Prolactin-induced Protein. Appl Immunohistochem Mol Morphol. 2019;27(7):508-514. https://doi.org/10.1097/PAI.0000000000000604.
Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S, et al. Assessment of Ki67 in breast Cancer: updated recommendations from the international Ki67 in breast Cancer working group. JNCI: J Natl Cancer Institute. 2020;113(7):808–19. https://doi.org/10.1093/jnci/djaa201.
Article
Google Scholar
Sakr RA, Barbashina V, Morrogh M, Chandarlapaty S, Andrade VP, Arroyo CD, et al. Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma. Appl Immunohistochem Mol Morphol. 2010;18(4):371–4. https://doi.org/10.1097/PAI.0b013e3181d50bd5.
Article
CAS
PubMed
PubMed Central
Google Scholar
Mingo J, Luna S, Gaafar A, Nunes-Xavier CE, Torices L, Mosteiro L, et al. Precise definition of PTEN C-terminal epitopes and its implications in clinical oncology. NPJ Precis Oncol. 2019;3(1):11. https://doi.org/10.1038/s41698-019-0083-4.
Article
PubMed
PubMed Central
Google Scholar
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4. https://doi.org/10.1158/2159-8290.CD-12-0095.
Article
Google Scholar
Lopez G, Costanza J, Colleoni M, Fontana L, Ferrero S, Miozzo M, et al. Molecular Insights into the Classification of Luminal Breast Cancers: The Genomic Heterogeneity of Progesterone-Negative Tumors. Int J Mol Sci. 2019;20(3). https://doi.org/10.3390/ijms20030510.
Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol. 2010;63(8):e1–37. https://doi.org/10.1016/j.jclinepi.2010.03.004.
Article
PubMed
Google Scholar
Fusco N, Vaira V, Righi I, Sajjadi E, Venetis K, Lopez G, et al. Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients. Lung Cancer. 2020;150:53–61. https://doi.org/10.1016/j.lungcan.2020.09.026.
Article
PubMed
Google Scholar
Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Int J Surg. 2012;10(1):28–55. https://doi.org/10.1016/j.ijsu.2011.10.001.
Article
PubMed
Google Scholar
Invernizzi M, Corti C, Lopez G, Michelotti A, Despini L, Gambini D, et al. Lymphovascular invasion and extranodal tumour extension are risk indicators of breast cancer related lymphoedema: an observational retrospective study with long-term follow-up. BMC Cancer. 2018;18(1):935. https://doi.org/10.1186/s12885-018-4851-2.
Article
PubMed
PubMed Central
Google Scholar
Invernizzi M, Michelotti A, Noale M, Lopez G, Runza L, Giroda M, et al. Breast Cancer Systemic Treatments and Upper Limb Lymphedema: A Risk-Assessment Platform Encompassing Tumor-Specific Pathological Features Reveals the Potential Role of Trastuzumab. J Clin Med. 2019;8(2):138.
Article
CAS
Google Scholar
Ngeow J, Eng C. PTEN in Hereditary and Sporadic Cancer. Cold Spring Harb Perspect Med. 2020;10(4). https://doi.org/10.1101/cshperspect.a036087.
Gozzelino L, De Santis MC, Gulluni F, Hirsch E, Martini M. PI(3,4)P2 signaling in Cancer and metabolism. Front Oncol. 2020;10:360. https://doi.org/10.3389/fonc.2020.00360.
Article
PubMed
PubMed Central
Google Scholar
Kechagioglou P, Papi RM, Provatopoulou X, Kalogera E, Papadimitriou E, Grigoropoulos P, et al. Tumor suppressor PTEN in breast cancer: heterozygosity, mutations and protein expression. Anticancer Res. 2014;34(3):1387–400.
CAS
PubMed
Google Scholar
Jones N, Bonnet F, Sfar S, Lafitte M, Lafon D, Sierankowski G, et al. Comprehensive analysis of PTEN status in breast carcinomas. Int J Cancer. 2013;133(2):323–34. https://doi.org/10.1002/ijc.28021.
Article
CAS
PubMed
Google Scholar
Beg S, Siraj AK, Prabhakaran S, Jehan Z, Ajarim D, Al-Dayel F, et al. Loss of PTEN expression is associated with aggressive behavior and poor prognosis in middle eastern triple-negative breast cancer. Breast Cancer Res Treat. 2015;151(3):541–53. https://doi.org/10.1007/s10549-015-3430-3.
Article
CAS
PubMed
Google Scholar
Grizzi G, Ghidini M, Botticelli A, Tomasello G, Ghidini A, Grossi F, et al. Strategies for increasing the effectiveness of aromatase inhibitors in locally advanced breast Cancer: an evidence-based review on current options. Cancer Manag Res. 2020;12:675–86. https://doi.org/10.2147/CMAR.S202965.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nicolini A, Ferrari P, Duffy MJ. Prognostic and predictive biomarkers in breast cancer: past, present and future. Semin Cancer Biol. 2018;52(Pt 1):56–73. https://doi.org/10.1016/j.semcancer.2017.08.010.
Article
CAS
PubMed
Google Scholar
Liang Y, Lin B, Ye Z, Chen S, Yu H, Chen C, et al. Triple-high expression of phosphatase and tensin homolog (PTEN), estrogen receptor (ER) and progesterone receptor (PR) may predict favorable prognosis for patients with type I endometrial carcinoma. J Cancer. 2020;11(6):1436–45. https://doi.org/10.7150/jca.33720.
Article
CAS
PubMed
PubMed Central
Google Scholar
Estrella JS, Broaddus RR, Mathews A, Milton DR, Yao JC, Wang H, et al. Progesterone receptor and PTEN expression predict survival in patients with low- and intermediate-grade pancreatic neuroendocrine tumors. Arch Pathol Lab Med. 2014;138(8):1027–36. https://doi.org/10.5858/arpa.2013-0195-OA.
Article
PubMed
Google Scholar
Hoxhaj G, Manning BD. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer. 2020;20(2):74–88. https://doi.org/10.1038/s41568-019-0216-7.
Article
CAS
PubMed
Google Scholar
Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR signaling in Cancer. Front Oncol. 2014;4:64.
Article
Google Scholar
Ramapriyan R, Caetano MS, Barsoumian HB, Mafra ACP, Zambalde EP, Menon H, et al. Altered cancer metabolism in mechanisms of immunotherapy resistance. Pharmacol Ther. 2019;195:162–71. https://doi.org/10.1016/j.pharmthera.2018.11.004.
Article
CAS
PubMed
Google Scholar
Venetis K, Piciotti R, Sajjadi E, Invernizzi M, Morganti S, Criscitiello C, et al. Breast Cancer with bone metastasis: molecular insights and clinical management. Cells. 2021;10(6):1377. https://doi.org/10.3390/cells10061377.
Article
PubMed
PubMed Central
Google Scholar
Milella M, Falcone I, Conciatori F, Cesta Incani U, Del Curatolo A, Inzerilli N, et al. PTEN: multiple functions in human malignant tumors. Front Oncol. 2015;5:24. https://doi.org/10.3389/fonc.2015.00024.
Article
PubMed
PubMed Central
Google Scholar
Naderali E, Khaki AA, Rad JS, Ali-Hemmati A, Rahmati M, Charoudeh HN. Regulation and modulation of PTEN activity. Mol Biol Rep. 2018;45(6):2869–81. https://doi.org/10.1007/s11033-018-4321-6.
Article
CAS
PubMed
Google Scholar
Song MS, Carracedo A, Salmena L, Song SJ, Egia A, Malumbres M, et al. Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner. Cell. 2011;144(2):187–99. https://doi.org/10.1016/j.cell.2010.12.020.
Article
CAS
PubMed
PubMed Central
Google Scholar
Pagni F, Guerini-Rocco E, Schultheis AM, Grazia G, Rijavec E, Ghidini M, et al. Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers. Int J Mol Sci. 2019;20(21). https://doi.org/10.3390/ijms20215452.
Razavi P, Dickler MN, Shah PD, Toy W, Brown DN, Won HH, et al. Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. Nat Cancer. 2020;1(4):382–93. https://doi.org/10.1038/s43018-020-0047-1.
Article
PubMed
PubMed Central
Google Scholar
Fan X, Kraynak J, Knisely JPS, Formenti SC, Shen WH. PTEN as a Guardian of the genome: pathways and targets. Cold Spring Harb Perspect Med. 2020;10(9). https://doi.org/10.1101/cshperspect.a036194.
Juric D, Castel P, Griffith M, Griffith OL, Won HH, Ellis H, et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kalpha inhibitor. Nature. 2015;518(7538):240–4. https://doi.org/10.1038/nature13948.
Article
CAS
PubMed
Google Scholar
Costa C, Wang Y, Ly A, Hosono Y, Murchie E, Walmsley CS, et al. PTEN loss mediates clinical cross-resistance to CDK4/6 and PI3Kalpha inhibitors in breast Cancer. Cancer Discov. 2020;10(1):72–85. https://doi.org/10.1158/2159-8290.CD-18-0830.
Article
CAS
PubMed
Google Scholar